Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts This week, 27 April 2025: Treatment-resistant hypertension Influenza transmission Nanoplastics in human brains Malaria elimination Chikungunya vaccine

Breast Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 14 articles: HTML format

Single Articles

April 2025
1. YUAN L, Zhu Y, Guan G, Liu M, et al
   Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function.
   Cancer Chemother Pharmacol. 2025;95:51.
   PubMed     Abstract available
   
   
   December 2024
2. ALANDAG C, Ozturk A, Yulak F, Sahin Inan ZD, et al
   HER-2 SMASH.
   Cancer Chemother Pharmacol. 2024;95:10.
   PubMed     Abstract available
   
   
   November 2024
3. LUO X, Wang N, Xing Y, Gao X, et al
   Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients.
   Cancer Chemother Pharmacol. 2024;94:721-732.
   PubMed     Abstract available
   
   
   August 2024
4. SALINAS-JAZMIN N, Medina-Mondragon MA, Jimenez-Lopez J, Guerrero-Rodriguez SL, et al
   Continuous exposure to doxorubicin induces stem cell-like characteristics and plasticity in MDA-MB-231 breast cancer cells identified with the SORE6 reporter.
   Cancer Chemother Pharmacol. 2024 Aug 24. doi: 10.1007/s00280-024-04701.
   PubMed     Abstract available
   
   
   
5. MARNI R, Malla M, Chakraborty A, Voonna MK, et al
   Combination of ionizing radiation and 2-thio-6-azauridine induces cell death in radioresistant triple negative breast cancer cells by downregulating CD151 expression.
   Cancer Chemother Pharmacol. 2024 Aug 21. doi: 10.1007/s00280-024-04709.
   PubMed     Abstract available
   
   
   
6. CHEN CS, Zirpoli G, Budd GT, Barlow WE, et al
   Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.
   Cancer Chemother Pharmacol. 2024;94:311-321.
   PubMed     Abstract available
   
   
   July 2024
7. YANG D, Xu G, Ding H, Zhong L, et al
   Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer.
   Cancer Chemother Pharmacol. 2024 Jul 31. doi: 10.1007/s00280-024-04702.
   PubMed     Abstract available
   
   
   
8. ISLAM MS, Akter F, Rahman MM, Rafe MR, et al
   Impact of ALDH1A1 and NQO1 gene polymorphisms on the response and toxicity of chemotherapy in Bangladeshi breast cancer patients.
   Cancer Chemother Pharmacol. 2024 Jul 16. doi: 10.1007/s00280-024-04700.
   PubMed     Abstract available
   
   
   
9. MALHI V, Nowicka M, Chen YC, Agarwal P, et al
   UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
   Cancer Chemother Pharmacol. 2024;94:117-122.
   PubMed     Abstract available
   
   
   June 2024
10. MOEIN A, Jin JY, Wright MR, Wong H, et al
    Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic bre
    Cancer Chemother Pharmacol. 2024 Jun 27. doi: 10.1007/s00280-024-04690.
    PubMed     Abstract available
    
    
    April 2024
11. GHORBANI M, Namazi S, Dehghani M, Razi F, et al
    Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients.
    Cancer Chemother Pharmacol. 2024 Apr 27. doi: 10.1007/s00280-024-04661.
    PubMed     Abstract available
    
    
    March 2024
12. ZHENG W, Peng W, Qian F, Zhang M, et al
    Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-kappaB signaling and reducing NLRP3 expression in triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2024 Mar 8. doi: 10.1007/s00280-024-04660.
    PubMed     Abstract available
    
    
    
13. YUCEL KB, Aydos U, Sutcuoglu O, Kilic ACK, et al
    Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
    Cancer Chemother Pharmacol. 2024 Mar 4. doi: 10.1007/s00280-024-04641.
    PubMed     Abstract available
    
    
    
14. MITTRA A, Coyne GHOS, Zlott J, Kummar S, et al
    Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
    Cancer Chemother Pharmacol. 2024;93:177-189.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.